Compare Guardant Health Inc. Common Stock (GH) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Guardant Health Inc. Common Stock vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Guardant Health Inc. Common Stock trades at $167.47 (market cap $22.22B), while Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B). The key difference: Guardant Health Inc. Common Stock is the larger of the two by market cap, and Halozyme Therapeutics Inc. Common Stock is more actively traded (2,179,278 versus 1,589,453). Which is the better fit depends on your goals — on Pluang, investors hold Guardant Health Inc. Common Stock for 1 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| GH | HALO | |
|---|---|---|
Market Cap | $22.22B | $12.58B |
Volume | 1,589,453 | 2,179,278 |
Sector | Health | Health |
52-Week High | $187.22 | $115.22 |
52-Week Low | $61.73 | $61.63 |
Typical Hold Time | 1 Days | 1 Days |
Enterprise Value | $22.86B | $14.49B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Guardant Health Inc. Common Stock
Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
